391 related articles for article (PubMed ID: 17363530)
1. A phase I/II study of arsenic trioxide/bortezomib/ascorbic acid combination therapy for the treatment of relapsed or refractory multiple myeloma.
Berenson JR; Matous J; Swift RA; Mapes R; Morrison B; Yeh HS
Clin Cancer Res; 2007 Mar; 13(6):1762-8. PubMed ID: 17363530
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of melphalan, arsenic trioxide and ascorbic acid combination therapy in patients with relapsed or refractory multiple myeloma: a prospective, multicentre, phase II, single-arm study.
Berenson JR; Boccia R; Siegel D; Bozdech M; Bessudo A; Stadtmauer E; Talisman Pomeroy J; Steis R; Flam M; Lutzky J; Jilani S; Volk J; Wong SF; Moss R; Patel R; Ferretti D; Russell K; Louie R; Yeh HS; Swift RA
Br J Haematol; 2006 Oct; 135(2):174-83. PubMed ID: 17010047
[TBL] [Abstract][Full Text] [Related]
3. Phase I/II trial assessing bortezomib and melphalan combination therapy for the treatment of patients with relapsed or refractory multiple myeloma.
Berenson JR; Yang HH; Sadler K; Jarutirasarn SG; Vescio RA; Mapes R; Purner M; Lee SP; Wilson J; Morrison B; Adams J; Schenkein D; Swift R
J Clin Oncol; 2006 Feb; 24(6):937-44. PubMed ID: 16418495
[TBL] [Abstract][Full Text] [Related]
4. A phase I study of samarium lexidronam/bortezomib combination therapy for the treatment of relapsed or refractory multiple myeloma.
Berenson JR; Yellin O; Patel R; Duvivier H; Nassir Y; Mapes R; Abaya CD; Swift RA
Clin Cancer Res; 2009 Feb; 15(3):1069-75. PubMed ID: 19188182
[TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy of bortezomib and melphalan combination in patients with relapsed or refractory multiple myeloma: updated results of a phase 1/2 study after longer follow-up.
Berenson JR; Yang HH; Vescio RA; Nassir Y; Mapes R; Lee SP; Wilson J; Yellin O; Morrison B; Hilger J; Swift R
Ann Hematol; 2008 Aug; 87(8):623-31. PubMed ID: 18463870
[TBL] [Abstract][Full Text] [Related]
6. Bortezomib, low-dose intravenous melphalan, and dexamethasone for patients with relapsed multiple myeloma.
Popat R; Oakervee H; Williams C; Cook M; Craddock C; Basu S; Singer C; Harding S; Foot N; Hallam S; Odeh L; Joel S; Cavenagh J
Br J Haematol; 2009 Mar; 144(6):887-94. PubMed ID: 19183191
[TBL] [Abstract][Full Text] [Related]
7. Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression.
Orlowski RZ; Nagler A; Sonneveld P; Bladé J; Hajek R; Spencer A; San Miguel J; Robak T; Dmoszynska A; Horvath N; Spicka I; Sutherland HJ; Suvorov AN; Zhuang SH; Parekh T; Xiu L; Yuan Z; Rackoff W; Harousseau JL
J Clin Oncol; 2007 Sep; 25(25):3892-901. PubMed ID: 17679727
[TBL] [Abstract][Full Text] [Related]
8. Bortezomib, ascorbic acid and melphalan (BAM) therapy for patients with newly diagnosed multiple myeloma: an effective and well-tolerated frontline regimen.
Berenson JR; Yellin O; Woytowitz D; Flam MS; Cartmell A; Patel R; Duvivier H; Nassir Y; Eades B; Abaya CD; Hilger J; Swift RA
Eur J Haematol; 2009 Jun; 82(6):433-9. PubMed ID: 19226361
[TBL] [Abstract][Full Text] [Related]
9. A Phase I study of arsenic trioxide (Trisenox), ascorbic acid, and bortezomib (Velcade) combination therapy in patients with relapsed/refractory multiple myeloma.
Held LA; Rizzieri D; Long GD; Gockerman JP; Diehl LF; de Castro CM; Moore JO; Horwitz ME; Chao NJ; Gasparetto C
Cancer Invest; 2013 Mar; 31(3):172-6. PubMed ID: 23406188
[TBL] [Abstract][Full Text] [Related]
10. Retreatment with bortezomib alone or in combination for patients with multiple myeloma following an initial response to bortezomib.
Sood R; Carloss H; Kerr R; Lopez J; Lee M; Druck M; Walters IB; Noga SJ
Am J Hematol; 2009 Oct; 84(10):657-60. PubMed ID: 19731393
[TBL] [Abstract][Full Text] [Related]
11. Tanespimycin and bortezomib combination treatment in patients with relapsed or relapsed and refractory multiple myeloma: results of a phase 1/2 study.
Richardson PG; Chanan-Khan AA; Lonial S; Krishnan AY; Carroll MP; Alsina M; Albitar M; Berman D; Messina M; Anderson KC
Br J Haematol; 2011 Jun; 153(6):729-40. PubMed ID: 21534941
[TBL] [Abstract][Full Text] [Related]
12. A phase I safety study of enzastaurin plus bortezomib in the treatment of relapsed or refractory multiple myeloma.
Ghobrial IM; Munshi NC; Harris BN; Shi P; Porter NM; Schlossman RL; Laubach JP; Anderson KC; Desaiah D; Myrand SP; Wooldridge JE; Richardson PG; Abonour R
Am J Hematol; 2011 Jul; 86(7):573-8. PubMed ID: 21630305
[TBL] [Abstract][Full Text] [Related]
13. High response rate to bortezomib with or without dexamethasone in patients with relapsed or refractory multiple myeloma: results of a global phase 3b expanded access program.
Mikhael JR; Belch AR; Prince HM; Lucio MN; Maiolino A; Corso A; Petrucci MT; Musto P; Komarnicki M; Stewart AK
Br J Haematol; 2009 Jan; 144(2):169-75. PubMed ID: 19036114
[TBL] [Abstract][Full Text] [Related]
14. "Short course" bortezomib plus melphalan and prednisone as induction prior to transplant or as frontline therapy for nontransplant candidates in patients with previously untreated multiple myeloma.
Gasparetto C; Gockerman JP; Diehl LF; de Castro CM; Moore JO; Long GD; Horwitz ME; Keogh G; Chute JP; Sullivan KM; Neuwirth R; Davis PH; Sutton LM; Anderson RD; Chao NJ; Rizzieri D
Biol Blood Marrow Transplant; 2010 Jan; 16(1):70-7. PubMed ID: 19733251
[TBL] [Abstract][Full Text] [Related]
15. Bortezomib in combination with conventional chemotherapeutic agents for multiple myeloma compared with bortezomib alone.
Min CK; Lee MJ; Eom KS; Lee S; Lee JW; Min WS; Kim CC; Kim M; Lim J; Kim Y; Han K
Jpn J Clin Oncol; 2007 Dec; 37(12):961-8. PubMed ID: 18156171
[TBL] [Abstract][Full Text] [Related]
16. Weekly treatment with bortezomib for patients with recurrent or refractory multiple myeloma: a phase 2 trial of the Minnie Pearl Cancer Research Network.
Hainsworth JD; Spigel DR; Barton J; Farley C; Schreeder M; Hon J; Greco FA
Cancer; 2008 Aug; 113(4):765-71. PubMed ID: 18543319
[TBL] [Abstract][Full Text] [Related]
17. A modified regimen of pegylated liposomal doxorubicin, bortezomib, and dexamethasone is effective and well tolerated in the treatment of relapsed or refractory multiple myeloma.
Waterman GN; Yellin O; Swift RA; Mapes R; Eades B; Ackerman E; Berenson JR
Ann Hematol; 2011 Feb; 90(2):193-200. PubMed ID: 20809423
[TBL] [Abstract][Full Text] [Related]
18. Bortezomib in combination with intermediate-dose dexamethasone and continuous low-dose oral cyclophosphamide for relapsed multiple myeloma.
Kropff M; Bisping G; Schuck E; Liebisch P; Lang N; Hentrich M; Dechow T; Kröger N; Salwender H; Metzner B; Sezer O; Engelhardt M; Wolf HH; Einsele H; Volpert S; Heinecke A; Berdel WE; Kienast J;
Br J Haematol; 2007 Aug; 138(3):330-7. PubMed ID: 17614819
[TBL] [Abstract][Full Text] [Related]
19. Perifosine plus bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma previously treated with bortezomib: results of a multicenter phase I/II trial.
Richardson PG; Wolf J; Jakubowiak A; Zonder J; Lonial S; Irwin D; Densmore J; Krishnan A; Raje N; Bar M; Martin T; Schlossman R; Ghobrial IM; Munshi N; Laubach J; Allerton J; Hideshima T; Colson K; Poradosu E; Gardner L; Sportelli P; Anderson KC
J Clin Oncol; 2011 Nov; 29(32):4243-9. PubMed ID: 21990396
[TBL] [Abstract][Full Text] [Related]
20. Bortezomib, doxorubicin, and dexamethasone combination therapy followed by thalidomide and dexamethasone consolidation as a salvage treatment for relapsed or refractory multiple myeloma: analysis of efficacy and safety.
Lee SS; Suh C; Kim BS; Chung J; Joo YD; Ryoo HM; Do YR; Jin JY; Kang HJ; Lee GW; Lee MH; Shim H; Kim K; Yoon SS; Bang SM; Kim HY; Lee JJ; Park J; Lee DS; Lee JH;
Ann Hematol; 2010 Sep; 89(9):905-12. PubMed ID: 20349060
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]